GTX Inc (GTXI) 1.44 $GTXI
GTx Provides Corporate Update and Reports First Quarter 2014 Financial Results
Business Wire - Thu May 08, 6:01AM CDT
GTx, Inc. (Nasdaq: GTXI) today provided a Company update and reported financial results for the first quarter of 2014.
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014: 33 Companies and 48 Drugs Profiled
M2 - Thu May 08, 4:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/grpwf5/metastatic) has announced the addition of the "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Companies Involved: - ATLAB Pharma SAS - AbbVie Inc. - Active Biotech AB - Astellas Pharma Inc. - AstraZeneca PLC - Bavarian Nordic A/S - Bellicum Pharmaceuticals, Inc. - Bind Therapeutics, Inc. - Bostwick Laboratories, Inc. - CellCentric Ltd. - CureVac GmbH - DexTech Medical AB - Eli Lilly and Company - Emergent BioSolutions Inc. - Exelixis, Inc. - GTx, Inc. - GenSpera, Inc. - Genentech, Inc. - Medivation, Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - NewLink Genetics Corporation - Novartis AG - Oncolytics Biotech Inc. - Oncothyreon Inc. - Onyx Pharmaceuticals, Inc. - Progenics Pharmaceuticals, Inc. - Sotio a.s. - Supratek Pharma Inc. - Synta Pharmaceuticals Corp. Drug Profiles: - enzalutamide - orteronel - custirsen sodium - tasquinimod - enzalutamide - cabozantinib (s)-malate - Prostvac - DCVAC/PCa - patupilone - DI-17-E-6 - olaratumab - navitoclax - vandetanib - PSMA ADC - GTx-758 - linsitinib - olaparib - panobinostat - carfilzomib - ganetespib - pelareorep - PX-866 - CV-9103 - G-202 - docetaxel targeted nanoparticles - buparlisib hydrochloride - NLG-8189 - Adenovirus/PSA Vaccine - TL-118 - CV-9104 For more information visit http://www.researchandmarkets.com/research/grpwf5/metastatic
GTX Inc. (GTXI) Jumps: Stock Up 14.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 7:51AM CDT
GTX Inc. (GTXI) was a big mover last session, as its shares rose over 14% on the day.
Traders Get Bullish on Shares of GTx, Shares Up 12.1% (GTXI)
Comtex SmarTrend(R) - Tue Apr 29, 10:10AM CDT
GTx (NASDAQ:GTXI) is one of today's best performing low-priced stocks, up 12.1% to $1.48 on 1.4x average daily volume. GTx has traded 832,000 shares thus far today, vs. average volume of 595,000 shares per day. The stock has outperformed the Dow (12.1% to the Dow's 0.5%) and outperformed the S&P 500 (12.1% to the S&P's 0.3%) during today's trading.
GTx, Inc. To Report First Quarter 2014 Financial Results On May 8, 2014
Business Wire - Thu Apr 24, 6:31AM CDT
GTx, Inc. (NASDAQ: GTXI) today announced that the timing for its first quarter 2014 financial results press release will be Thursday, May 8, 2014, prior to the opening of the U.S. stock markets. The Company is not planning to host a conference call or webcast on that date, but will continue to provide periodic updates on clinical trial results and other material company developments as appropriate throughout the remainder of the year.
Stock to Watch: GTx Down 7.2% (GTXI)
Comtex SmarTrend(R) - Mon Apr 07, 10:42AM CDT
GTx (NASDAQ:GTXI) is one of today's worst performing low-priced stocks, down 7.2% to $1.41 on 1.4x average daily volume. Thus far today, GTx has traded 904,000 shares, vs. average volume of 633,000 shares per day. The stock has underperformed the Dow (-7.2% to the Dow's -0.7%) and underperformed the S&P 500 (-7.2% to the S&P's -0.6%) during today's trading.
GTx Announces Departure of CEO
Business Wire - Fri Apr 04, 5:25AM CDT
--- Marc Hanover, GTx's President and COO, named interim CEO -
GTx Down 7.9%, Shares Slide into the Red (GTXI)
Comtex SmarTrend(R) - Thu Mar 27, 12:45PM CDT
GTx (NASDAQ:GTXI) is one of today's worst performing low-priced stocks, down 7.9% to $1.51 on 1.4x average daily volume. Thus far today, GTx has traded 874,000 shares, vs. average volume of 604,000 shares per day. The stock has underperformed the Dow (-7.9% to the Dow's -0.1%) and underperformed the S&P 500 (-7.9% to the S&P's -0.3%) during today's trading.
Strength Seen in GTX (GTXI): Stock Moves 8.8% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 8:46AM CDT
GTX was a big mover last session, with shares rising nearly 9% on the day.
GTx Up 8.5%, Shares Break Through Resistance (GTXI)
Comtex SmarTrend(R) - Thu Mar 13, 10:17AM CDT
GTx (NASDAQ:GTXI) is one of today's best performing low-priced stocks, up 8.5% to $1.91 on 2.5x average daily volume. GTx has traded 1.3 million shares thus far today, vs. average volume of 506,000 shares per day. The stock has outperformed the Dow (8.5% to the Dow's -0.2%) and outperformed the S&P 500 (8.5% to the S&P's -0.2%) during today's trading.
GTx, Inc. Announces Closing of Private Placement
Business Wire - Thu Mar 06, 4:05PM CST
GTx, Inc. (NASDAQ: GTXI) announced today that it closed the previously-announced private placement of its common stock and warrants to purchase its common stock. In the private placement, GTx issued 11,976,048 immediately separable units, comprised of an aggregate of 11,976,048 newly-issued shares of common stock and warrants to purchase up to 10,179,642 additional shares of common stock. The purchasers consisted of J.R. Hyde, III, the chairman of GTx's Board of Directors, and The Pyramid Peak Foundation. Gross proceeds from the offering were approximately $21.3 million.
Narrower-than-Expected Q4 Loss at GTx - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 8:50AM CST
GTx, reported fourth quarter 2013 net loss per share of 12 cents, narrower than the Zacks Consensus Estimate of a loss of 13 cents
GTx Announces Webcast of Corporate Presentation at 26TH Annual ROTH Conference
Business Wire - Wed Mar 05, 6:30AM CST
GTx, Inc. (Nasdaq: GTXI) announced today that management will present a company overview on March 11, 2014 at the 26th Annual ROTH Conference in Dana Point, CA. The GTx presentation will begin at 1:00 p.m. EDT. A simultaneous webcast of the presentation will be accessible from the GTx website at http://www.gtxinc.com. An archived replay of the presentation will be available on the company website until March 25, 2014.
GTx Provides Corporate Update and Reports 2013 Financial Results
Business Wire - Tue Mar 04, 6:00AM CST
GTx, Inc. (Nasdaq: GTXI) today provided a Company update and reported financial results for the fourth quarter and full year 2013.
GTx, Inc. Announces Pricing of Private Placement
Business Wire - Tue Mar 04, 5:30AM CST
GTx, Inc. (NASDAQ: GTXI) announced today that it has entered into a securities purchase agreement with J.R. Hyde, III, the chairman of GTx's Board of Directors, and The Pyramid Peak Foundation, to issue and sell in a private placement to these purchasers an aggregate of 11,976,048 immediately separable units, comprised of an aggregate of 11,976,048 shares of GTx common stock and warrants to purchase up to 10,179,642 additional shares of common stock. The total purchase price payable to GTx for the units is $21,272,455.42, or approximately $1.77625 per unit. The warrants, which may only be exercised for cash, will have a per share exercise price of $1.67 (equal to the closing bid price of GTx's common stock on March 3, 2014) and a one year term. The closing of the private placement will occur three business days following the satisfaction or waiver of customary closing conditions as set forth in the securities purchase agreement, or on such other date as the purchasers in the private placement may agree upon. The securities purchase agreement will terminate if the closing of the private placement has not occurred on or prior to April 15, 2014, provided that the purchasers in the private placement may, in their sole discretion, extend such date to August 15, 2014.
GTx Announces Webcast of Corporate Presentation at Cowen and Company 34th Annual Health Care Conference
Business Wire - Wed Feb 26, 6:30AM CST
GTx, Inc. (Nasdaq: GTXI) announced today that management will present a company overview on March 5, 2014 at the Cowen and Company 34th Annual Health Care Conference in Boston. The GTx presentation will begin at 8.00 a.m. EST. A simultaneous webcast of the presentation will be accessible from the GTx website at http://www.gtxinc.com. An archived replay of the presentation will be available on the company website until March 19, 2014.
Cancer Cachexia - Pipeline Review, H2 2013 Research Report
M2 - Tue Feb 25, 2:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/smbrv3/cancer_cachexia) has announced the addition of the "Cancer Cachexia - Pipeline Review, H2 2013" report to their offering. 'Cancer Cachexia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cancer Cachexia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cancer Cachexia. Scope - A snapshot of the global therapeutic scenario for Cancer Cachexia. - A review of the Cancer Cachexia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cancer Cachexia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Cancer Cachexia Overview Therapeutics Development Pipeline Products for Cancer Cachexia - Overview Drug Profiles enobosarm - Drug Profile anamorelin hydrochloride - Drug Profile Xilonix - Drug Profile macimorelin acetate - Drug Profile clazakizumab - Drug Profile anamorelin hydrochloride - Drug Profile (megestrol formoterol) - Drug Profile (etodolac propranolol) - Drug Profile OHR/AVR-118 - Drug Profile MT-102 - Drug Profile LY-2495655 - Drug Profile bimagrumab - Drug Profile IP-1510 - Drug Profile IP-1510 - Drug Profile dronabinol - Drug Profile tertomotide - Drug Profile Ghrelin Receptor Agonists - Drug Profile Drug Targeting Vps34 - Drug Profile L-379 - Drug Profile Activin Type IIB Receptor Antagonist - Drug Profile DCB-CA2 - Drug Profile Drug For Cancer Cachexia - Drug Profile Drug Targeting Glutaminase - Drug Profile Drugs For Cancer Cachexia - Drug Profile Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Amgen Inc. Eli Lilly and Company Novartis AG Aphios Corporation GTx, Inc. AEterna Zentaris Inc. Helsinn Healthcare S.A. Alder Biopharmaceuticals Inc. Vicus Therapeutics, LLC Ohr Pharmaceutical Inc. KAEL-GemVax Co., Ltd. XBiotech USA, Inc. Acacia Pharma Ltd. PsiOxus Therapeutics, Ltd. Signablok, Inc Myomics, Inc. Sprint Bioscience AB Itis Pharmaceuticals Pty Ltd For more information visit http://www.researchandmarkets.com/research/sm...r_cachexia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
GTx, Inc. To Host Fourth Quarter and Full Year 2013 Financial Results Conference Call and Webcast
Business Wire - Tue Feb 18, 6:30AM CST
GTx, Inc. (NASDAQ: GTXI) today announced that it will host a conference call and webcast to provide a corporate update and discuss the Company's fourth quarter and full year 2013 financial results on Tuesday, March 4, 2014, at 9:00 a.m. Eastern Time. The call and webcast will follow the release of the financial results earlier that day.
Retinopathy - Pipeline Review, H2 2013 Research Report
M2 - Wed Feb 05, 2:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/rr9skm/retinopathy) has announced the addition of the "Retinopathy - Pipeline Review, H2 2013" report to their offering. 'Retinopathy - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Retinopathy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Retinopathy. Scope - A snapshot of the global therapeutic scenario for Retinopathy. - A review of the Retinopathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Retinopathy pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Some Key Topics Covered: Introduction Retinopathy Overview Therapeutics Development Pipeline Products for Retinopathy - Overview Pipeline Products for Retinopathy - Comparative Analysis Retinopathy - Therapeutics under Development by Companies Retinopathy - Therapeutics under Investigation by Universities/Institutes Retinopathy - Pipeline Products Glance Retinopathy - Therapeutics Assessment Assessment by Monotherapy Products Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Assessment by Therapeutic Class Mutants Of Pigment Epithelium Derived Factor - Drug Profile Retinopathy - Dormant Projects Retinopathy - Discontinued Products Retinopathy - Product Development Milestones Companies Mentioned GTx, Inc. Affichem SIFI S.p.A TWi Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/rr...etinopathy About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
GTx Provides Corporate Update and Reports First Quarter 2014 Financial Results
Business Wire - Thu May 08, 6:01AM CDT
GTx, Inc. (Nasdaq: GTXI) today provided a Company update and reported financial results for the first quarter of 2014.
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014: 33 Companies and 48 Drugs Profiled
M2 - Thu May 08, 4:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/grpwf5/metastatic) has announced the addition of the "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Companies Involved: - ATLAB Pharma SAS - AbbVie Inc. - Active Biotech AB - Astellas Pharma Inc. - AstraZeneca PLC - Bavarian Nordic A/S - Bellicum Pharmaceuticals, Inc. - Bind Therapeutics, Inc. - Bostwick Laboratories, Inc. - CellCentric Ltd. - CureVac GmbH - DexTech Medical AB - Eli Lilly and Company - Emergent BioSolutions Inc. - Exelixis, Inc. - GTx, Inc. - GenSpera, Inc. - Genentech, Inc. - Medivation, Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - NewLink Genetics Corporation - Novartis AG - Oncolytics Biotech Inc. - Oncothyreon Inc. - Onyx Pharmaceuticals, Inc. - Progenics Pharmaceuticals, Inc. - Sotio a.s. - Supratek Pharma Inc. - Synta Pharmaceuticals Corp. Drug Profiles: - enzalutamide - orteronel - custirsen sodium - tasquinimod - enzalutamide - cabozantinib (s)-malate - Prostvac - DCVAC/PCa - patupilone - DI-17-E-6 - olaratumab - navitoclax - vandetanib - PSMA ADC - GTx-758 - linsitinib - olaparib - panobinostat - carfilzomib - ganetespib - pelareorep - PX-866 - CV-9103 - G-202 - docetaxel targeted nanoparticles - buparlisib hydrochloride - NLG-8189 - Adenovirus/PSA Vaccine - TL-118 - CV-9104 For more information visit http://www.researchandmarkets.com/research/grpwf5/metastatic
GTX Inc. (GTXI) Jumps: Stock Up 14.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 7:51AM CDT
GTX Inc. (GTXI) was a big mover last session, as its shares rose over 14% on the day.
Traders Get Bullish on Shares of GTx, Shares Up 12.1% (GTXI)
Comtex SmarTrend(R) - Tue Apr 29, 10:10AM CDT
GTx (NASDAQ:GTXI) is one of today's best performing low-priced stocks, up 12.1% to $1.48 on 1.4x average daily volume. GTx has traded 832,000 shares thus far today, vs. average volume of 595,000 shares per day. The stock has outperformed the Dow (12.1% to the Dow's 0.5%) and outperformed the S&P 500 (12.1% to the S&P's 0.3%) during today's trading.
GTx, Inc. To Report First Quarter 2014 Financial Results On May 8, 2014
Business Wire - Thu Apr 24, 6:31AM CDT
GTx, Inc. (NASDAQ: GTXI) today announced that the timing for its first quarter 2014 financial results press release will be Thursday, May 8, 2014, prior to the opening of the U.S. stock markets. The Company is not planning to host a conference call or webcast on that date, but will continue to provide periodic updates on clinical trial results and other material company developments as appropriate throughout the remainder of the year.
Stock to Watch: GTx Down 7.2% (GTXI)
Comtex SmarTrend(R) - Mon Apr 07, 10:42AM CDT
GTx (NASDAQ:GTXI) is one of today's worst performing low-priced stocks, down 7.2% to $1.41 on 1.4x average daily volume. Thus far today, GTx has traded 904,000 shares, vs. average volume of 633,000 shares per day. The stock has underperformed the Dow (-7.2% to the Dow's -0.7%) and underperformed the S&P 500 (-7.2% to the S&P's -0.6%) during today's trading.
GTx Announces Departure of CEO
Business Wire - Fri Apr 04, 5:25AM CDT
--- Marc Hanover, GTx's President and COO, named interim CEO -
GTx Down 7.9%, Shares Slide into the Red (GTXI)
Comtex SmarTrend(R) - Thu Mar 27, 12:45PM CDT
GTx (NASDAQ:GTXI) is one of today's worst performing low-priced stocks, down 7.9% to $1.51 on 1.4x average daily volume. Thus far today, GTx has traded 874,000 shares, vs. average volume of 604,000 shares per day. The stock has underperformed the Dow (-7.9% to the Dow's -0.1%) and underperformed the S&P 500 (-7.9% to the S&P's -0.3%) during today's trading.
Strength Seen in GTX (GTXI): Stock Moves 8.8% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 8:46AM CDT
GTX was a big mover last session, with shares rising nearly 9% on the day.
GTx Up 8.5%, Shares Break Through Resistance (GTXI)
Comtex SmarTrend(R) - Thu Mar 13, 10:17AM CDT
GTx (NASDAQ:GTXI) is one of today's best performing low-priced stocks, up 8.5% to $1.91 on 2.5x average daily volume. GTx has traded 1.3 million shares thus far today, vs. average volume of 506,000 shares per day. The stock has outperformed the Dow (8.5% to the Dow's -0.2%) and outperformed the S&P 500 (8.5% to the S&P's -0.2%) during today's trading.
GTx, Inc. Announces Closing of Private Placement
Business Wire - Thu Mar 06, 4:05PM CST
GTx, Inc. (NASDAQ: GTXI) announced today that it closed the previously-announced private placement of its common stock and warrants to purchase its common stock. In the private placement, GTx issued 11,976,048 immediately separable units, comprised of an aggregate of 11,976,048 newly-issued shares of common stock and warrants to purchase up to 10,179,642 additional shares of common stock. The purchasers consisted of J.R. Hyde, III, the chairman of GTx's Board of Directors, and The Pyramid Peak Foundation. Gross proceeds from the offering were approximately $21.3 million.
Narrower-than-Expected Q4 Loss at GTx - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 8:50AM CST
GTx, reported fourth quarter 2013 net loss per share of 12 cents, narrower than the Zacks Consensus Estimate of a loss of 13 cents
GTx Announces Webcast of Corporate Presentation at 26TH Annual ROTH Conference
Business Wire - Wed Mar 05, 6:30AM CST
GTx, Inc. (Nasdaq: GTXI) announced today that management will present a company overview on March 11, 2014 at the 26th Annual ROTH Conference in Dana Point, CA. The GTx presentation will begin at 1:00 p.m. EDT. A simultaneous webcast of the presentation will be accessible from the GTx website at http://www.gtxinc.com. An archived replay of the presentation will be available on the company website until March 25, 2014.
GTx Provides Corporate Update and Reports 2013 Financial Results
Business Wire - Tue Mar 04, 6:00AM CST
GTx, Inc. (Nasdaq: GTXI) today provided a Company update and reported financial results for the fourth quarter and full year 2013.
GTx, Inc. Announces Pricing of Private Placement
Business Wire - Tue Mar 04, 5:30AM CST
GTx, Inc. (NASDAQ: GTXI) announced today that it has entered into a securities purchase agreement with J.R. Hyde, III, the chairman of GTx's Board of Directors, and The Pyramid Peak Foundation, to issue and sell in a private placement to these purchasers an aggregate of 11,976,048 immediately separable units, comprised of an aggregate of 11,976,048 shares of GTx common stock and warrants to purchase up to 10,179,642 additional shares of common stock. The total purchase price payable to GTx for the units is $21,272,455.42, or approximately $1.77625 per unit. The warrants, which may only be exercised for cash, will have a per share exercise price of $1.67 (equal to the closing bid price of GTx's common stock on March 3, 2014) and a one year term. The closing of the private placement will occur three business days following the satisfaction or waiver of customary closing conditions as set forth in the securities purchase agreement, or on such other date as the purchasers in the private placement may agree upon. The securities purchase agreement will terminate if the closing of the private placement has not occurred on or prior to April 15, 2014, provided that the purchasers in the private placement may, in their sole discretion, extend such date to August 15, 2014.
GTx Announces Webcast of Corporate Presentation at Cowen and Company 34th Annual Health Care Conference
Business Wire - Wed Feb 26, 6:30AM CST
GTx, Inc. (Nasdaq: GTXI) announced today that management will present a company overview on March 5, 2014 at the Cowen and Company 34th Annual Health Care Conference in Boston. The GTx presentation will begin at 8.00 a.m. EST. A simultaneous webcast of the presentation will be accessible from the GTx website at http://www.gtxinc.com. An archived replay of the presentation will be available on the company website until March 19, 2014.
Cancer Cachexia - Pipeline Review, H2 2013 Research Report
M2 - Tue Feb 25, 2:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/smbrv3/cancer_cachexia) has announced the addition of the "Cancer Cachexia - Pipeline Review, H2 2013" report to their offering. 'Cancer Cachexia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cancer Cachexia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cancer Cachexia. Scope - A snapshot of the global therapeutic scenario for Cancer Cachexia. - A review of the Cancer Cachexia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cancer Cachexia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Cancer Cachexia Overview Therapeutics Development Pipeline Products for Cancer Cachexia - Overview Drug Profiles enobosarm - Drug Profile anamorelin hydrochloride - Drug Profile Xilonix - Drug Profile macimorelin acetate - Drug Profile clazakizumab - Drug Profile anamorelin hydrochloride - Drug Profile (megestrol formoterol) - Drug Profile (etodolac propranolol) - Drug Profile OHR/AVR-118 - Drug Profile MT-102 - Drug Profile LY-2495655 - Drug Profile bimagrumab - Drug Profile IP-1510 - Drug Profile IP-1510 - Drug Profile dronabinol - Drug Profile tertomotide - Drug Profile Ghrelin Receptor Agonists - Drug Profile Drug Targeting Vps34 - Drug Profile L-379 - Drug Profile Activin Type IIB Receptor Antagonist - Drug Profile DCB-CA2 - Drug Profile Drug For Cancer Cachexia - Drug Profile Drug Targeting Glutaminase - Drug Profile Drugs For Cancer Cachexia - Drug Profile Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Amgen Inc. Eli Lilly and Company Novartis AG Aphios Corporation GTx, Inc. AEterna Zentaris Inc. Helsinn Healthcare S.A. Alder Biopharmaceuticals Inc. Vicus Therapeutics, LLC Ohr Pharmaceutical Inc. KAEL-GemVax Co., Ltd. XBiotech USA, Inc. Acacia Pharma Ltd. PsiOxus Therapeutics, Ltd. Signablok, Inc Myomics, Inc. Sprint Bioscience AB Itis Pharmaceuticals Pty Ltd For more information visit http://www.researchandmarkets.com/research/sm...r_cachexia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
GTx, Inc. To Host Fourth Quarter and Full Year 2013 Financial Results Conference Call and Webcast
Business Wire - Tue Feb 18, 6:30AM CST
GTx, Inc. (NASDAQ: GTXI) today announced that it will host a conference call and webcast to provide a corporate update and discuss the Company's fourth quarter and full year 2013 financial results on Tuesday, March 4, 2014, at 9:00 a.m. Eastern Time. The call and webcast will follow the release of the financial results earlier that day.
Retinopathy - Pipeline Review, H2 2013 Research Report
M2 - Wed Feb 05, 2:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/rr9skm/retinopathy) has announced the addition of the "Retinopathy - Pipeline Review, H2 2013" report to their offering. 'Retinopathy - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Retinopathy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Retinopathy. Scope - A snapshot of the global therapeutic scenario for Retinopathy. - A review of the Retinopathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Retinopathy pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Some Key Topics Covered: Introduction Retinopathy Overview Therapeutics Development Pipeline Products for Retinopathy - Overview Pipeline Products for Retinopathy - Comparative Analysis Retinopathy - Therapeutics under Development by Companies Retinopathy - Therapeutics under Investigation by Universities/Institutes Retinopathy - Pipeline Products Glance Retinopathy - Therapeutics Assessment Assessment by Monotherapy Products Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Assessment by Therapeutic Class Mutants Of Pigment Epithelium Derived Factor - Drug Profile Retinopathy - Dormant Projects Retinopathy - Discontinued Products Retinopathy - Product Development Milestones Companies Mentioned GTx, Inc. Affichem SIFI S.p.A TWi Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/rr...etinopathy About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
